January 8, 2019
Chicago, Jan. 8, 2019 – SAMDI Tech, Inc., the industry’s leading provider of label-free drug discovery solutions, has promoted Michael D. Scholle to chief operating officer. Formerly serving as director and later as vice president of operations and technology, Scholle brings more than two decades of experience across all aspects of drug discovery research to his expanded role as SAMDI Tech’s new COO.
“Michael’s passion for enhancing the treatment of human disease and his long history at SAMDI Tech have helped us become the company we are today,” said Emilio Córdova, PhD, MBA, chief executive officer at SAMDI Tech. “As a founding member and valued colleague, we trust his leadership to take SAMDI technology and our clients who use our label-free assays to new heights.”
“As COO, my goal is to further inspire the industry to escape the confines of traditional drug discovery solutions,” said Scholle. “I look forward to further enabling and supporting our team’s mission in providing clients with outstanding, high-quality and innovative label-free services that quickly move drug programs toward the clinic.”
Scholle holds Bachelor of Science and Master of Science degrees from Northern Illinois University and a Master of Business Administration degree from Roosevelt University-Chicago.
About SAMDI Tech
SAMDI Tech Inc. delivers better, faster and label-free assay development, high-throughput screening and peptide substrate discovery solutions for early-stage drug candidate selection. Our highly skilled team believes in results and uses proprietary industry-leading, label-free SAMDI (Self-Assembled Monolayer Desorption Ionization) technology to deliver decision-making data fast. Learn more about SAMDI Tech at www.samditech.com.